September 16, 2022
With IPO plans on hold following the failed listing attempt in 2020, Bridgepoint is now (again) working on a sale of renal care provider Diaverum with Citi advising according to multiple sources - 2021 revenue of EUR 876m (+2.9% year-on-year) and Pro-forma EBITA of EUR 144m (NKP Proprietary)
NKP | M&A Insights Proprietary
Headline from pre-deal coverage in M&A Insights